Ra-SBRT is Potential Immune Adjuvant for Innate Immune Cell Populations in Advance Stage NSCLC Patients . Journal of Analytical Oncology, [S. l.], v. 8, p. 71–76, 2019. DOI: 10.30683/1927-7229.2019.08.10. Disponível em: https://www.neoplasiaresearch.com/index.php/jao/article/view/193. Acesso em: 17 apr. 2026.